Mati Chuamanochan

Dr. Mati Chuamanochan

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
PPPhichayut Phinyo
Phichayut Phinyo
PKPattaraporn Koompawichit
Pattaraporn Koompawichit
SNSurapon Nochaiwong
Surapon Nochaiwong
NTNapatra Tovanabutra
Napatra Tovanabutra
SCSiri Chiewchanvit
Siri Chiewchanvit
MCMati Chuamanochan
Mati Chuamanochan

25 August 2021 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
SNSurapon Nochaiwong
Surapon Nochaiwong
MCMati Chuamanochan
Mati Chuamanochan
CRChidchanok Ruengorn
Chidchanok Ruengorn
RARatanaporn Awiphan
Ratanaporn Awiphan
NTNapatra Tovanabutra
Napatra Tovanabutra
SCSiri Chiewchanvit
Siri Chiewchanvit
Quiz Ref ID Chronic spontaneous urticaria (CSU) is the most common form of chronic urticaria, characterized by recurrent hives (wheals) and/or angioedema lasting more than 6 weeks, without any specific eliciting triggers.1 In addition to disease severity and significant morbidity, CSU can be challenging, with significant morbidity and impaired health-related quality of life. Moreover, evidence suggests that CSU affects patients’ socioeconomic status, particularly with substantial loss of productivity at school, work, or daily life, due to the unpredictable nature of the disease.2 Despite the widespread use of various effective nonsedating second-generation H1 antihistamines for the management of CSU over the past decade,3 less than half of patients receive adequate treatment with licensed doses of second-generation H1 antihistamines.4

12 August 2021 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
PKPiranit Kantaputra
Piranit Kantaputra
SCSuteeraporn Chaowattanapanit
Suteeraporn Chaowattanapanit
SKSalin Kiratikanon
Salin Kiratikanon
RCRomanee Chaiwarith
Romanee Chaiwarith
CCChareon Choonhakarn
Chareon Choonhakarn
MCMati Chuamanochan
Mati Chuamanochan

23 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SNSurapon Nochaiwong
Surapon Nochaiwong
MCMati Chuamanochan
Mati Chuamanochan
CRChidchanok Ruengorn
Chidchanok Ruengorn
KNKajohnsak Noppakun
Kajohnsak Noppakun
RARatanaporn Awiphan
Ratanaporn Awiphan
GKGreg A. Knoll
Greg A. Knoll
Background: The use of thiazide diuretics is associated with skin cancer risk; however, whether this applies to all skin cancer types is unclear. Methods: In this meta-analysis, we searched multiple electronic databases and gray literature up to 10 April 2022, with no language restrictions, to identify relevant randomized controlled trials (RCTs) and non-randomized studies (cohort, case-control) that investigated the association between thiazide diuretics and skin cancer. The primary outcomes of interest were malignant melanoma and non-melanoma skin cancer (basal cell carcinoma [BCC], squamous cell carcinoma [SCC]). Secondary outcomes included other skin cancers (lip cancer, Merkel cell carcinoma, malignant adnexal skin tumors, oral cavity cancer, and precursors of skin cancer). We used a random-effects meta-analysis to estimate pooled adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Results: Thirty non-randomized studies (17 case-control, 13 cohort, no RCTs) were included. Thiazide diuretic users had a higher risk of malignant melanoma (17 studies; n = 10,129,196; pooled adjusted OR, 1.10; 95% CI, 1.04–1.15; p < 0.001; strength of evidence, very low; very small harmful effect), BCC (14 studies; n = 19,780,476; pooled adjusted OR, 1.05; 95% CI, 1.02–1.09; p = 0.003; strength of evidence, very low; very small harmful effect), and SCC (16 studies; n = 16,387,862; pooled adjusted OR, 1.35; 95% CI, 1.22–1.48; p < 0.001; strength of evidence, very low; very small harmful effect) than non-users. Thiazide diuretic use was also associated with a higher risk of lip cancer (5 studies; n = 161,491; pooled adjusted OR, 1.92; 95% CI, 1.52–2.42; p < 0.001; strength of evidence, very low; small harmful effect), whereas other secondary outcomes were inconclusive. Conclusions: Thiazide diuretics are associated with the risk of all skin cancer types, including malignant melanoma; thus, they should be used with caution in clinical practice.

14 April 2023 in Experimental Dermatology
Verified
Journal Article
Open access
LCLeena Chularojanamontri
Leena Chularojanamontri
KRKrittaya Rattanakorn
Krittaya Rattanakorn
NJNarachai Julanon
Narachai Julanon
MCMati Chuamanochan
Mati Chuamanochan
Chris EM GriffithsChris EM Griffiths
Chris EM Griffiths
Pustular psoriasis is characterised by eruptions of neutrophilic sterile pustules. The European Rare and Severe Psoriasis Expert Network consensus defines pustular psoriasis into three subtypes; generalised pustular psoriasis (GPP), palmoplantar pustulosis and acrodermatitis continua of Hallopeau (ACH). Mixed forms are categorised according to their predominant features. However, the Japanese Dermatological Association includes ACH under the diagnosis of GPP. This article aims to review the similarities and differences between ACH and GPP. Based on our review, interleukin (IL)‐36RN mutations, the most frequent genetic findings in pustular psoriasis are found most commonly in GPP, followed by ACH. Genotypes of IL‐36RN mutations among GPP patients and ACH patients are different between European and Asian ethnicities. IL‐36 signalling pathway is the main mechanism. Metabolic diseases are common comorbidities and joint involvement can occur in 20.5%–36.4% of both conditions. Associated plaque psoriasis is more common in GPP than in ACH. Generally, ACH, even the generalised type, does not have systemic inflammation whereas GPP can occur with or without systemic inflammation. ACH can occur before, simultaneously, or after the development of GPP. However, response to treatment for GPP and ACH even in the same patients appear to be different. ACH seemed to be more recalcitrant to treatment than GPP but severe flare of GPP can lead to morbidity and mortality. Although GPP and ACH share genotypes and pathogenesis, we believe that ACH should be classified separately from GPP, and not under diagnosis of GPP. Future research is warranted to satisfactorily distinguish the two conditions.

23 April 2023 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
WCWasuchon Chaichan
Wasuchon Chaichan
CRChidchanok Ruengorn
Chidchanok Ruengorn
KTKednapa Thavorn
Kednapa Thavorn
BHBrian Hutton
Brian Hutton
JSJacek C. Szepietowski
Jacek C. Szepietowski
SNSurapon Nochaiwong
Surapon Nochaiwong